Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Artiva Biotherapeutics, Inc. Common Stock (ARTV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/09/2025: ARTV (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $15.4
1 Year Target Price $15.4
| 4 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -19.34% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 41.17M USD | Price to earnings Ratio - | 1Y Target Price 15.4 |
Price to earnings Ratio - | 1Y Target Price 15.4 | ||
Volume (30-day avg) 6 | Beta - | 52 Weeks Range 1.47 - 17.31 | Updated Date 07/9/2025 |
52 Weeks Range 1.47 - 17.31 | Updated Date 07/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.04 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -33.3% | Return on Equity (TTM) -68.14% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -110793329 | Price to Sales(TTM) 214.51 |
Enterprise Value -110793329 | Price to Sales(TTM) 214.51 | ||
Enterprise Value to Revenue 7.54 | Enterprise Value to EBITDA - | Shares Outstanding 24363100 | Shares Floating 5916827 |
Shares Outstanding 24363100 | Shares Floating 5916827 | ||
Percent Insiders 19.99 | Percent Institutions 89.73 |
Upturn AI SWOT
Artiva Biotherapeutics, Inc. Common Stock
Company Overview
History and Background
Artiva Biotherapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing allogeneic natural killer (NK) cell therapies to treat cancer. Founded in 2019, Artiva is advancing a pipeline of off-the-shelf NK cell therapies designed to be readily available and scalable to address significant unmet needs in oncology.
Core Business Areas
- Allogeneic NK Cell Therapies: Develops and commercializes allogeneic, or off-the-shelf, NK cell therapies for cancer treatment. This includes cell engineering and manufacturing processes.
- Partnered Programs: Collaborates with pharmaceutical companies to develop and commercialize NK cell therapies targeting specific cancer indications.
Leadership and Structure
The leadership team is composed of experienced biopharmaceutical executives with backgrounds in cell therapy development and commercialization. The organizational structure includes research and development, manufacturing, clinical development, and business development functions.
Top Products and Market Share
Key Offerings
- AB-101: An off-the-shelf, cryopreserved, allogeneic NK cell therapy candidate being developed for the treatment of relapsed or refractory B-cell lymphomas. Competitors include other companies developing allogeneic cell therapies, such as Fate Therapeutics and Nkarta. Currently in Phase 1/2 clinical trials, therefore market share data and revenue figures are not currently available.
- AB-102: AB-102 is another NK cell therapy candidate engineered with CAR (chimeric antigen receptor). Preclinical trials are underway. Revenue figures and market share data are not currently available. Competitors include other companies developing allogeneic cell therapies, such as Fate Therapeutics and Nkarta.
Market Dynamics
Industry Overview
The cell therapy industry is rapidly growing, driven by increasing demand for innovative cancer treatments. Allogeneic cell therapies offer advantages over autologous therapies, including scalability and reduced manufacturing costs.
Positioning
Artiva is positioned as a leader in the allogeneic NK cell therapy space, with a focus on developing scalable and readily available therapies. Their competitive advantage lies in their proprietary manufacturing platform and strategic partnerships.
Total Addressable Market (TAM)
The total addressable market for cell therapies in oncology is estimated to be in the tens of billions of dollars annually. Artiva is positioning itself to capture a significant share of this market through its innovative NK cell therapies.
Upturn SWOT Analysis
Strengths
- Proprietary NK cell therapy platform
- Scalable manufacturing process
- Strategic partnerships with pharmaceutical companies
- Experienced management team
Weaknesses
- Early stage clinical development
- High cash burn rate
- Dependence on strategic partnerships
- Limited commercial experience
Opportunities
- Expanding clinical trials into new indications
- Securing regulatory approvals for lead product candidates
- Expanding strategic partnerships
- Advancing manufacturing capabilities
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other cell therapy companies
- Manufacturing challenges
Competitors and Market Share
Key Competitors
- NKarta, Inc. (NKTX)
- Fate Therapeutics (FATE)
- Gamida Cell Ltd. (GMDA)
Competitive Landscape
Artiva competes with other cell therapy companies developing allogeneic NK cell therapies. Their competitive advantage lies in their proprietary platform, scalable manufacturing process, and strategic partnerships. They are in the development stage and not yet generating revenue.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by investment in research and development, clinical trial progress, and securing strategic partnerships.
Future Projections: Future growth is dependent on the successful development and commercialization of NK cell therapies. Analyst estimates vary based on clinical trial outcomes and regulatory approvals.
Recent Initiatives: Recent initiatives include advancing clinical trials for lead product candidates, expanding manufacturing capabilities, and exploring new strategic partnerships.
Summary
Artiva Biotherapeutics is a promising clinical-stage biopharmaceutical company focused on allogeneic NK cell therapies. It has a proprietary platform and strategic partnerships but is still early in its development. Successful clinical trials and regulatory approvals are key to its future growth, but also potential risks that could result in significant loss. The competition is heating up and there are many companies also working on cell therapies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Artiva Biotherapeutics, Inc. SEC Filings
- Company Website
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor. Market share data is estimated and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Artiva Biotherapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2024-07-19 | President, CEO & Director Dr. Fred Aslan M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 96 | Website https://www.artivabio.com |
Full time employees 96 | Website https://www.artivabio.com | ||
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.